Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
Biomerica (NASDAQ: BMRA) has secured three key patent allowances in European markets for its inFoods® Technology, targeting GERD, Crohn's Disease, and Ulcerative Colitis. The patents cover major European markets including Germany, UK, France, Italy, Spain, and over 30 other EPO nations. These markets represent significant opportunities: GERD ($4B+ annually), Crohn's Disease ($2.5B+ annually), and Ulcerative Colitis (projected $1.9B by 2028). The inFoods® Technology platform identifies specific foods triggering symptoms in patients, enabling personalized dietary plans as alternatives to traditional medications, particularly addressing concerns over PPI side effects in GERD treatment.
Biomerica (NASDAQ: BMRA) ha ottenuto tre importanti concessioni di brevetto nei mercati europei per la sua tecnologia inFoods®, mirata a GERD, malattia di Crohn e colite ulcerosa. I brevetti coprono i principali mercati europei, tra cui Germania, Regno Unito, Francia, Italia, Spagna e oltre 30 altre nazioni dell'EPO. Questi mercati rappresentano opportunità significative: GERD (oltre 4 miliardi di dollari annuali), malattia di Crohn (oltre 2,5 miliardi di dollari all'anno) e colite ulcerosa (proiettata a 1,9 miliardi di dollari entro il 2028). La piattaforma tecnologica inFoods® identifica alimenti specifici che scatenano sintomi nei pazienti, consentendo piani dietetici personalizzati come alternative ai farmaci tradizionali, affrontando in particolare le preoccupazioni riguardo agli effetti collaterali degli PPI nel trattamento della GERD.
Biomerica (NASDAQ: BMRA) ha obtenido tres concesiones de patente clave en los mercados europeos para su tecnología inFoods®, enfocándose en GERD, la enfermedad de Crohn y la colitis ulcerosa. Las patentes cubren los principales mercados europeos, incluyendo Alemania, Reino Unido, Francia, Italia, España y más de 30 otras naciones de la EPO. Estos mercados representan oportunidades significativas: GERD (más de 4 mil millones de dólares anuales), la enfermedad de Crohn (más de 2.5 mil millones de dólares anuales) y la colitis ulcerosa (proyectada a 1.9 mil millones de dólares para 2028). La plataforma tecnológica inFoods® identifica alimentos específicos que desencadenan síntomas en los pacientes, permitiendo planes dietéticos personalizados como alternativas a los medicamentos tradicionales, abordando especialmente las preocupaciones sobre los efectos secundarios de los PPI en el tratamiento de la GERD.
Biomerica (NASDAQ: BMRA)는 GERD, 크론병 및 궤양성 대장염을 타겟으로 하는 inFoods® 기술에 대해 유럽 시장에서 세 가지 주요 특허 승인을 확보했습니다. 이 특허는 독일, 영국, 프랑스, 이탈리아, 스페인 및 30개 이상의 EPO 국가를 포함한 주요 유럽 시장을 포괄합니다. 이 시장들은 중요한 기회를 나타냅니다: GERD(연간 40억 달러 이상), 크론병(연간 25억 달러 이상), 궤양성 대장염(2028년까지 19억 달러 예측). inFoods® 기술 플랫폼은 환자의 증상을 유발하는 특정 음식을 식별하여, 전통적인 약물에 대한 대안으로 개인화된 식단 계획을 가능하게 하며, 특히 GERD 치료에서 PPI의 부작용에 대한 우려를 해결합니다.
Biomerica (NASDAQ: BMRA) a sécurisé trois concessions de brevets clés sur les marchés européens pour sa technologie inFoods®, ciblant la GERD, la maladie de Crohn et la colite ulcéreuse. Les brevets couvrent les principaux marchés européens, y compris l'Allemagne, le Royaume-Uni, la France, l'Italie, l'Espagne et plus de 30 autres pays de l'OEB. Ces marchés représentent des opportunités significatives : GERD (plus de 4 milliards de dollars par an), la maladie de Crohn (plus de 2,5 milliards de dollars par an) et la colite ulcéreuse (prévision de 1,9 milliard de dollars d'ici 2028). La plateforme technologique inFoods® identifie des aliments spécifiques déclenchant des symptômes chez les patients, permettant des plans diététiques personnalisés comme alternatives aux médicaments traditionnels, répondant particulièrement aux préoccupations concernant les effets secondaires des PPI dans le traitement de la GERD.
Biomerica (NASDAQ: BMRA) hat drei wichtige Patenterteilungen auf den europäischen Märkten für seine inFoods®-Technologie gesichert, die sich auf GERD, Morbus Crohn und Colitis ulcerosa konzentriert. Die Patente decken die wichtigsten europäischen Märkte ab, darunter Deutschland, das Vereinigte Königreich, Frankreich, Italien, Spanien und über 30 weitere EPO-Staaten. Diese Märkte bieten bedeutende Chancen: GERD (jährlich über 4 Milliarden USD), Morbus Crohn (jährlich über 2,5 Milliarden USD) und Colitis ulcerosa (prognostiziert auf 1,9 Milliarden USD bis 2028). Die inFoods®-Technologieplattform identifiziert spezifische Lebensmittel, die bei Patienten Symptome auslösen, und ermöglicht personalisierte Ernährungspläne als Alternativen zu herkömmlichen Medikamenten, wobei insbesondere Bedenken hinsichtlich der Nebenwirkungen von PPI bei der GERD-Behandlung angesprochen werden.
- Secured three strategic patents in major European markets
- Access to large market opportunities: GERD ($4B+), Crohn's Disease ($2.5B+), Ulcerative Colitis ($1.9B)
- Technology offers safer alternative to PPIs which have serious side effects
- Already has 15 patents globally for IBS treatment
- Patent issuance depends on additional fees and completion of required steps
- Company may not proceed with issuance in all eligible countries due to strategic prioritization
Insights
The patent approvals for inFoods® Technology mark a significant milestone for Biomerica's expansion into major gastrointestinal markets. The technology addresses
The most compelling aspect is the potential alternative to PPIs for GERD treatment, given recent concerns about their long-term safety profile and links to serious conditions like Alzheimer's. The diagnostic-guided approach could significantly reduce healthcare costs while improving patient outcomes through personalized dietary interventions. However, market penetration will depend on clinical validation and healthcare provider adoption.
These patent allowances significantly strengthen Biomerica's intellectual property portfolio across key European markets. The addressable market opportunity is substantial, with GERD alone representing a
The strategic value lies in the company's ability to leverage existing infrastructure from their IBS product to accelerate market entry for these new indications. However, investors should note that patent issuance is contingent on fee payments and the company may selectively prioritize certain markets based on commercial potential and resource allocation.
- New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD (
$4 billion +), Crohn’s Disease ($2.5 billion +), and Ulcerative Colitis ($1.9 billion +)
- The company received three notices of allowance in countries within the European Patent Organization (EPO), including Germany, UK, France, Italy, Spain, and over 30 additional nations within the European Patent Treaty
IRVINE, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical technology company, announces they have recently received three patent notices of allowance covering technology and methods for treating Gastroesophageal Reflux Disease (“GERD”), Crohn’s Disease, and Ulcerative Colitis using its proprietary inFoods® Technology. These patents apply to countries under the European Patent Organization (“EPO”), including major markets such as Germany, UK, France, Italy, and Spain, as well as over 30 other nations within the EPO.
Prevalence and Market Potential in Europe
GERD, Crohn’s Disease and Ulcerative Colitis represent significant worldwide healthcare challenges across Europe.
GERD: The GERD treatment market in Europe exceeds
Crohn’s Disease: The market for Crohn’s Disease treatments in Europe is estimated at
Ulcerative Colitis: The European market size of
These recent notices of allowance and issuance of patents are a significant milestone in Biomerica's mission to enhance patient care through personalized medical solutions. The Company is currently marketing an inFoods® Technology test to treat IBS sufferers, which is already covered by 15 different patents globally. The issuance of patents in these additional disease states opens the door for Biomerica to complete development of inFoods therapeutic products to treat patients within this broader spectrum of gastrointestinal diseases.
inFoods®: A Personalized and Safer Approach to GI Care
Biomerica’s inFoods® Technology is a diagnostic-guided platform that identifies specific foods in each patient that trigger worsening symptoms in GERD, Crohn’s Disease, and Ulcerative Colitis. This allows healthcare providers to create personalized dietary plans, addressing the root cause of symptoms and reducing reliance on medications with severe side effects.
For GERD: inFoods® offers an alternative to proton pump inhibitors (“PPIs”), which are widely prescribed despite their links to dementia, Alzheimer’s, and kidney disease. This non-drug, dietary-based solution is a safer option for millions of patients.
For Crohn’s and Ulcerative Colitis: inFoods® supports tailored dietary interventions that work alongside traditional pharmaceutical therapies, potentially reducing symptom severity, healthcare costs, and improving overall quality of life.
“With these European patents, Biomerica can expand its GI offerings to address GERD, Crohn’s, and Ulcerative Colitis,” said Zack Irani, CEO of Biomerica. “inFoods® represents a paradigm shift in gastrointestinal care, offering safer, non-drug solutions that align with the growing demand for personalized medicine. This achievement underscores our dedication to enhancing patient outcomes and creating value for our investors.”
The issuance of each patent in individual countries, following approval by the respective national patent authorities, depends on the Company completing required steps, such as payment of the necessary patent issuance fees. In some cases, the Company may strategically prioritize certain countries within the EPO or other regions and may not proceed with issuance in every eligible country. For more information about Biomerica and the inFoods® platform, please visit www.biomerica.com and www.infoods.com.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primary focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
About inFoods®
The Biomerica inFoods® IBS product is designed to allow physicians to identify patient-specific foods (e.g., eggs, broccoli, wheat, potatoes, pork, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. This patented, diagnostic-guided therapy is designed to allow for a patient-specific, guided dietary regimen to improve IBS outcomes. A point-of-care version of the product is being developed to allow physicians to perform the test in-office using a finger stick blood sample, while a clinical lab version of the product is expected to be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is already available for inFoods® products. Since the inFoods® product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects. An estimated 45 million people in America currently suffer from IBS making it a leading cause for patient doctor visits.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to current and future issuance of patents, the Company proceeding with issuance of every patent in every approved country, including issuance in every member nation within the EPO, freedom to operate in specific diseases and/or regions, efficacy of the Company’s patents at limiting competition, breadth of coverage these patents provide, the efficacy of the Company’s inFoods products in treating patients suffering from various gastrointestinal diseases, and the efficacy of the Company’s other tests, future FDA clearance of the Company’s products, the rapidity of testing results, negotiations with international distribution partners, uniqueness of the Company’s products, accuracy of inFoods test result, demand for domestic or international orders, potential revenues from the sale of current or future products, availability of the Company’s test kits, and timing of the commercial launch of various inFoods tests. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: the Company’s ability or willingness to pay, or continue to pay the patent issuance fees, and/or pay the patent’s annual maintenance fees, results of studies testing the efficacy of the Company’s inFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company’s products; domestic or international availability of the Company’s test kits and other products; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; the Company’s ability to comply with current and future regulations in the countries where our products are made and sold and the Company’s ability to obtain additional patent protection on any aspects of its rapid test technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.
Corporate Contact:
Zack Irani
Biomerica
949-645-2111
Source: Biomerica, Inc.
FAQ
What markets will Biomerica's (BMRA) new patents cover in Europe?
What is the market size for GERD treatment that Biomerica (BMRA) is targeting in Europe?
How does Biomerica's (BMRA) inFoods Technology work for gastrointestinal diseases?
What is the projected market size for Ulcerative Colitis treatment that Biomerica (BMRA) can address?
